Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,862.50
-0.35%
DAX
26,323.88
0.00%
CAC 40
8,726.03
0.00%
STOXX 50
6,535.62
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Friday 26 August 2022 2:19 pm  |  Updated:  Friday 26 August 2022 4:08 pm

Moderna to sue Pfizer over Covid vaccine tech

By: Leah Montebello

Add as a preferred source on Google
Moderna suing Pfizer over Covid vaccine technology
Moderna suing Pfizer over Covid vaccine technology

Moderna has said it will be suing Pfizer and its German partner BioNTech for patent infringement for the first Covid-19 vaccine.

The US firm claims that the mRNA technology it developed before the pandemic was copied by the companies.

The lawsuit has been filed in Germany and Massachusetts in the US.

“Moderna believes that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna’s foundational mRNA technology,” the company said ina. news release.

“This groundbreaking technology was critical to the development of Moderna’s own mRNA COVID-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty.”

Moderna and Pfizer’s vaccines have been crucial to the global rollout of vaccines, with Pfizer making up the majority of administered doses in the US.

Both vaccines are used in the UK, as well as AstraZeneca. As of March 2022, more than 52m people had had their first vaccine dose. More than 49m – or 85 per cent of over-12s – had both doses.

Pfizer said in a statement this afternoon: “Pfizer/BioNTech has not yet fully reviewed the complaint but we are surprised by the litigation given the Pfizer/BioNTech COVID-19 Vaccine was based on BioNTech’s proprietary mRNA technology and developed by both BioNTech and Pfizer.

We remain confident in our intellectual property supporting the Pfizer/BioNTech vaccine and will vigorously defend against the allegations of the lawsuit.”

Read more

Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Vaccine

Trending Articles

  • Boutique London advisory firm lands £8m funding amid M&A frenzy

  • Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

  • Point2 Completes $136M Series B Funding with Arm, LB Investment, and Maverick Silicon

  • Top economists shun Burnham over wealth taxes

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

More from Morning Wire

  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • Lufthansa and aviation rivals clash in London court over power outlet profits

    Legal
    Lufthansa aircraft on tarmac with logo visible, showcasing airlines fleet under clear sky in a business news context
  • UK debt ‘hits £3 trillion’ milestone

    Economics
    Houses of Parliament in Westminster showcasing historic architecture under a clear sky, central to UK government and politics
  • Apple gears up for fresh legal fight with government

    Lawsuit
    Apple unveils new products at recent event showcasing innovative technology and sleek design to global audience
  • I’m an editor. This is the most worrying thing about AI slop

    Life&Style
    Young woman drawing or writing at a desk, surrounded by art supplies, illustrating human creativity vs AI.
  • Anthropic payout piles pressure on UK ministers in AI copyright row

    Tech
    Smartphone displaying the Claude by Anthropic AI assistant app, showing the app icon and interface.
  • From crown jewel to €180m courtroom battle: The investor revolt targeting Atos

    Markets
    Atos logo prominently displayed on a modern office building, highlighting its corporate presence and technological expertise.
  • Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook